Peptron, Inc. (KOSDAQ:087010)

Market Cap	6.07T +146.0%
Revenue (ttm)	5.63B +78.8%
Net Income	-13.82B
EPS	-595.00
Shares Out	23.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	120,482
Average Volume	119,173
Open	267,500
Previous Close	270,000
Day's Range	260,000 - 275,500
52-Week Range	151,000 - 392,500
Beta	0.75
RSI	43.87
Earnings Date	n/a

About Peptron

Peptron, Inc. engages in the development of peptide-based medicines. The company’s technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. It develops PAb 001 for cancer therapy; SR-Exenatide (PT320) for Parkinson’s and other neurodegenerative disease; SR-Octreotide for the treatment of acromegaly; and Dernak filler for bioequivalence. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 087010

Financial Performance

In 2025, Peptron's revenue was 5.63 billion, an increase of 78.76% compared to the previous year's 3.15 billion. Losses were -13.82 billion, -37.26% less than in 2024.